Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pyruvate dehydrogenase E1 subunit beta (PDHB)
- Target
- PDHB
- Molecular classification
- Enzyme, Mitochondrial enzyme complex component
01
Overview
Pyruvate dehydrogenase E1 subunit beta (PDHB) is a protein-coding mitochondrial enzyme that forms part of the heterotetrameric E1 component of the pyruvate dehydrogenase (PDH) complex, which includes two alpha and two beta subunits. The PDH complex catalyzes the irreversible conversion of pyruvate to acetyl-CoA and CO2, providing a crucial link between glycolysis and the tricarboxylic acid (TCA) cycle, and thus is central to eukaryotic energy metabolism. PDHB deficiencies, often due to inherited mutations, result in pyruvate dehydrogenase deficiency characterized by lactic acidosis and diverse neurological impairments. Recent studies associate PDHB expression with cancer diagnosis, prognosis, and immune microenvironment modulation, making it a novel biomarker and potential therapeutic target for a variety of tumors[1][2][3].
- Other names
- Pyruvate dehydrogenase (lipoamide) betaPyruvate dehydrogenase E1 component subunit beta, mitochondrialPDHE1-BE1-betaPHE1BPDHE1BPDHBDPyruvate dehydrogenase, E1 beta polypeptideEpididymis secretory sperm binding protein
02
Mechanism of action
Activation or inhibition of PDH complex to modulate pyruvate to acetyl-CoA conversion Inhibition of pyruvate dehydrogenase kinase (by dichloroacetate) increases PDHB complex activity to enhance glucose oxidation
03
Biological functions
Central metabolism (glycolysis to TCA cycle)Energy production (ATP generation)Oxidative decarboxylation of pyruvate
04
Disease associations
CancerPyruvate dehydrogenase E1-beta deficiencyLeigh syndromeLeukoencephalopathy with ovarian failureLactic acidosis
05
Safety considerations
Essential role in intermediary metabolism poses risk of severe metabolic disturbances (e.g., lactic acidosis) if systemically inhibitedMutations cause severe neurological deficiency syndromes
06
Interacting drugs
Dichloroacetate (experimental modulator of pyruvate dehydrogenase complex activity)
1 more in the full profile.
07
Biomarkers
Differential expression of PDHB as a diagnostic and prognostic marker in multiple cancers, including kidney, breast, liver, brain, ovarian, and pancreatic cancersAssociated with tumor stage, immune cell infiltration, immune checkpoint gene expression, and molecular subtypes in certain tumors
Beyond the preview
Go deeper on Pyruvate dehydrogenase E1 subunit beta (PDHB).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pyruvate dehydrogenase E1 subunit beta (PDHB).